Deucravacitinib Improves Patient-Reported Outcomes for Psoriatic Arthritis

The study presented results from the patient perspective by evaluating patient-reported outcomes. 

Deucravacitinib, a TYK-2 inhibitor, was linked with significant improvements in patient-reported outcomes (PROs) in patients with active psoriatic arthritis (PsA), according to results from a phase 2 trial.

To assess the effects of deucravacitinib in this patient population, the study authors conducted a double-blind and randomized trial that included 203 patients with active PsA who were assigned to receive either deucravacitinib at doses of 6 mg or 12 mg once daily or a placebo over a period of 16 weeks. Key secondary endpoints included changes from baseline at Week 16 in the Health Assessment Questionnaire Disability Index (HAQ-DI) and the 36-item Short Form Health Survey (SF-36) physical component summary (PCS) score. Additional PROs (fatigue, pain, and mental health) were also assessed.

The results showed that both doses of deucravacitinib led to significant improvements in HAQ-DI and SF-36 PCS scores compared to the placebo group. Moreover, a higher proportion of patients receiving deucravacitinib reported improvements meeting minimum clinically important differences (MCIDs) or reaching scores equal to or greater than normative values for various PROs.

"Deucravacitinib demonstrated significant and clinically meaningful improvements in PROs versus placebo in patients with active PsA and warrants further study," the authors wrote.

The study was published in Arthritis Care & Research (a journal of the American College of Rheumatology).

Source: Strand V, Gossec L, Coates LC, et al. Improvements in patient‐reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial. Arthritis Care & Research. Published online March 26, 2024. Doi:https://doi.org/10.1002/acr.25333